DE69512036T2 - Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns-reparaturenzyminhibitoren - Google Patents
Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns-reparaturenzyminhibitorenInfo
- Publication number
- DE69512036T2 DE69512036T2 DE69512036T DE69512036T DE69512036T2 DE 69512036 T2 DE69512036 T2 DE 69512036T2 DE 69512036 T DE69512036 T DE 69512036T DE 69512036 T DE69512036 T DE 69512036T DE 69512036 T2 DE69512036 T2 DE 69512036T2
- Authority
- DE
- Germany
- Prior art keywords
- adp
- parp
- dna repair
- compounds
- adprt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/16—Compounds containing azido groups with azido groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9404485A GB9404485D0 (en) | 1994-03-09 | 1994-03-09 | Benzamide analogues |
PCT/GB1995/000513 WO1995024379A1 (en) | 1994-03-09 | 1995-03-09 | Benzamide analogs, useful as parp (adp-ribosyltransferase, adprt) dna repair enzyme inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69512036D1 DE69512036D1 (de) | 1999-10-14 |
DE69512036T2 true DE69512036T2 (de) | 1999-12-30 |
Family
ID=10751492
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69524641T Expired - Fee Related DE69524641T2 (de) | 1994-03-09 | 1995-03-09 | Benzamidanaloga zur Verwendung als PARP- (ADP-Ribosyltransferase, ADPRT) DNS-Reparaturenzym Inhibitoren |
DE69529482T Expired - Fee Related DE69529482T2 (de) | 1994-03-09 | 1995-03-09 | Chinazoline als Chemotherapeutika |
DE69512036T Expired - Fee Related DE69512036T2 (de) | 1994-03-09 | 1995-03-09 | Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns-reparaturenzyminhibitoren |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69524641T Expired - Fee Related DE69524641T2 (de) | 1994-03-09 | 1995-03-09 | Benzamidanaloga zur Verwendung als PARP- (ADP-Ribosyltransferase, ADPRT) DNS-Reparaturenzym Inhibitoren |
DE69529482T Expired - Fee Related DE69529482T2 (de) | 1994-03-09 | 1995-03-09 | Chinazoline als Chemotherapeutika |
Country Status (13)
Country | Link |
---|---|
US (3) | US5756510A (de) |
EP (3) | EP0897915B1 (de) |
JP (1) | JPH09510704A (de) |
CN (1) | CN1081624C (de) |
AT (3) | ATE231494T1 (de) |
CA (1) | CA2184747C (de) |
DE (3) | DE69524641T2 (de) |
DK (2) | DK0749415T3 (de) |
ES (2) | ES2169472T3 (de) |
GB (1) | GB9404485D0 (de) |
GR (1) | GR3031886T3 (de) |
PT (1) | PT879820E (de) |
WO (1) | WO1995024379A1 (de) |
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372770B1 (en) | 1994-10-12 | 2002-04-16 | Euro-Celtique, S.A. | Benzoxazoles |
US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
WO1998027975A1 (en) * | 1996-12-20 | 1998-07-02 | Geron Corporation | Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence |
GB9702701D0 (en) * | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
DE19726824C1 (de) * | 1997-06-24 | 1999-03-04 | Deutsches Krebsforsch | Verfahren zur Identifizierung kanzerogener Agenzien |
US6346536B1 (en) | 1997-09-03 | 2002-02-12 | Guilford Pharmaceuticals Inc. | Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same |
WO1999011622A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
US20020028813A1 (en) * | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
WO1999011644A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6235748B1 (en) | 1997-09-03 | 2001-05-22 | Guilford Pharmaceuticals Inc. | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
US6121278A (en) * | 1997-09-03 | 2000-09-19 | Guilford Pharmaceuticals, Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
FR2776291B1 (fr) * | 1998-03-18 | 2000-06-16 | Pf Medicament | Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament |
US6380193B1 (en) | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
EP1077944A1 (de) * | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Carboxamide verbindungen,methode und zusammensetzungen zur hemmung derparp-aktivitaet |
CA2332239A1 (en) * | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
US6395749B1 (en) | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
IL143112A0 (en) | 1998-12-01 | 2002-04-21 | Univ Kentucky Res Found | A method for enhancing protective cellular responses to genotoxic stress in skin |
US6201020B1 (en) | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
PL210415B1 (pl) | 1999-01-11 | 2012-01-31 | Agouron Pharma | Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US6444676B1 (en) | 1999-12-20 | 2002-09-03 | Iok-Hou Pang | Use of PARP inhibitors in the treatment of glaucoma |
DE60144277D1 (de) * | 2000-04-25 | 2011-05-05 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
AU2001264595A1 (en) | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
WO2001091796A2 (en) | 2000-06-01 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Methods, compounds and compositions for treating gout |
US6545011B2 (en) | 2000-07-13 | 2003-04-08 | Guilford Pharmaceuticals Inc. | Substituted 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones, derivatives thereof and their uses |
GB0017508D0 (en) | 2000-07-17 | 2000-08-30 | Novartis Ag | Antimicrobials |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
US6660858B2 (en) | 2001-03-28 | 2003-12-09 | Lion Bioscience Ag | 2-aminobenzoxazole derivatives and combinatorial libraries thereof |
JP2005501848A (ja) * | 2001-08-15 | 2005-01-20 | アイコス コーポレイション | 2h−フタラジン−1−オンおよびその使用方法 |
US6753428B2 (en) | 2001-11-20 | 2004-06-22 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
AUPR975601A0 (en) * | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
JP2005529076A (ja) * | 2002-02-15 | 2005-09-29 | サイトキネティクス・インコーポレーテッド | キナゾリノンの合成 |
DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
WO2003097053A1 (en) | 2002-05-09 | 2003-11-27 | Cytokinetics, Inc. | Compounds, compositions, and methods |
MXPA04011074A (es) * | 2002-05-09 | 2005-06-08 | Cytokinetics Inc | Compuestos de pirimidinona, composiciones y metodos. |
EP1513820A4 (de) * | 2002-05-23 | 2006-09-13 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren |
CA2489367A1 (en) * | 2002-06-14 | 2003-12-24 | Cytokinetics, Inc. | Compounds, compositions, and methods |
WO2004009036A2 (en) * | 2002-07-23 | 2004-01-29 | Cytokinetics, Inc. | Compounds compositions and methods |
JP2005536553A (ja) * | 2002-08-21 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
JP2006501306A (ja) * | 2002-09-30 | 2006-01-12 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
CA2500952C (en) * | 2002-10-04 | 2011-04-26 | Prana Biotechnology Limited | Neurologically-active compounds |
AU2002951868A0 (en) * | 2002-10-04 | 2002-10-24 | Prana Biotechnology Limited | Compound i |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
BRPI0408996A (pt) * | 2003-03-31 | 2006-03-28 | Pfizer | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
JP2007510652A (ja) * | 2003-11-03 | 2007-04-26 | サイトキネティクス・インコーポレーテッド | ピリミジン−4−オン化合物、組成物、および方法 |
US20050148593A1 (en) * | 2003-11-07 | 2005-07-07 | Gustave Bergnes | Compounds, compositions, and methods |
EA009875B1 (ru) | 2003-11-20 | 2008-04-28 | Янссен Фармацевтика Н.В. | 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы |
BRPI0416817A (pt) | 2003-11-20 | 2007-03-06 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas 7-fenilalquila substituìdas como inibidores da poli(adp-ribose)polimerase |
DK2305221T3 (en) | 2003-12-01 | 2015-08-24 | Kudos Pharm Ltd | DNA damage repair inhibitors for the treatment of cancer |
WO2005061460A1 (en) * | 2003-12-08 | 2005-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
WO2006003148A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as parp inhibitors |
EP1771422B1 (de) | 2004-06-30 | 2011-02-16 | Janssen Pharmaceutica NV | Chinazolinonderivate als parp-hemmer |
CA2569824C (en) | 2004-06-30 | 2013-03-19 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as parp inhibitors |
CN100431606C (zh) * | 2004-11-22 | 2008-11-12 | 山东蓝金生物工程有限公司 | 一种抗癌药物组合物 |
GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
EP1868595B1 (de) * | 2005-04-01 | 2012-01-11 | Wellstat Therapeutics Corporation | Verbindungen zur behandlung von stoffwechselstörungen |
US20070015814A1 (en) * | 2005-06-10 | 2007-01-18 | Ernest Kun | Parp Modulators and Treatment of Cancer |
ZA200800907B (en) * | 2005-07-18 | 2010-04-28 | Bipar Sciences Inc | Treatment of cancer |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
JP5221368B2 (ja) * | 2005-11-14 | 2013-06-26 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク(セエヌエールエス) | Parp活性のインヒビター及びその使用 |
US8560350B2 (en) * | 2005-11-22 | 2013-10-15 | Robert J. Nadai | Method, system and computer program product for generating an electronic bill having optimized insurance claim items |
US20140039920A1 (en) * | 2005-11-22 | 2014-02-06 | Robert J. Nadai | Methodology, system and computer program product for generating electronic insurance claims or bills, having optimized insurance claim items in order to maximize reimbursement and to facilitate approval of the claim(s) upon first submission to the insurance carrier |
NZ590271A (en) | 2006-04-14 | 2011-12-22 | Prana Biotechnology Ltd | 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-ones and 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-thiones |
WO2007137000A2 (en) * | 2006-05-16 | 2007-11-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combination cancer chemotherapy |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
CA2655257A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
EP2041087A1 (de) * | 2006-06-15 | 2009-04-01 | Kudos Pharmaceuticals Limited | 2-oxybenzamidderivate ls parp-inhibitoren |
JP2010502730A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ,インコーポレイティド | 癌の治療法 |
US7994222B2 (en) * | 2006-09-05 | 2011-08-09 | Bipar Sciences, Inc. | Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール |
AU2008223793B2 (en) | 2007-03-08 | 2012-08-23 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
CN101809017A (zh) | 2007-09-14 | 2010-08-18 | 阿斯利康(瑞典)有限公司 | 酞嗪酮衍生物 |
PL2215075T3 (pl) | 2007-10-26 | 2014-04-30 | Janssen Pharmaceutica Nv | Pochodne chinolinonu jako inhibitory PARP |
MX2010005221A (es) * | 2007-11-12 | 2010-09-28 | Bipar Sciences Inc | Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales. |
JP2011503111A (ja) * | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ,インコーポレイティド | Parp阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
KR20100102637A (ko) * | 2007-12-07 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | 토포이소머라제 억제제 및 parp 억제제의 병용물에 의한 암의 치료 |
KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-{4-[(3s)-피페리딘-3-일]페닐}-2h-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
EP2250282A4 (de) * | 2008-02-04 | 2011-05-18 | Bipar Sciences Inc | Verfahren zur diagnose und behandlung von parp-vermittelten krankheiten |
CN101998959B (zh) * | 2008-02-06 | 2013-08-28 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂 |
CN101531638B (zh) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
EP2260026B1 (de) | 2008-03-27 | 2011-06-22 | Janssen Pharmaceutica, N.V. | Chinazolinonderivate als tubulinpolymerisationshemmer |
EP2271626B1 (de) | 2008-03-27 | 2014-11-26 | Janssen Pharmaceutica, N.V. | Tetrahydrophenanthridinone und tetrahydrocyclopentachinolinone als parp- und tubulinpolymerisierungshemmer |
CN101628913B (zh) * | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
EP2346495B2 (de) | 2008-10-07 | 2023-05-24 | Kudos Pharmaceuticals Limited | Pharmazeutische formulierung 514 |
AU2009313878B2 (en) | 2008-11-13 | 2016-01-07 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
WO2010083220A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzoxazole inhibitors of poly(adp-ribose)polymerase |
BRPI1012333A2 (pt) | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
US8546409B2 (en) | 2009-04-20 | 2013-10-01 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
CN102647987A (zh) | 2009-07-21 | 2012-08-22 | 吉里德卡利斯托加公司 | 使用pi3k抑制剂治疗肝脏障碍 |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
CN102382097B (zh) * | 2010-09-03 | 2013-08-07 | 中国科学院上海药物研究所 | 芳甲胺类衍生物及其药物组合物、制备方法和用途 |
BR112013005223A2 (pt) | 2010-09-03 | 2016-05-03 | Bayer Ip Gmbh | "pirimidinonas e dihidropirimidinonas fusionadas substituídas." |
WO2013064083A1 (en) * | 2011-11-01 | 2013-05-10 | Impact Therapeutics, Inc. | 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof |
CN102531946A (zh) * | 2012-01-05 | 2012-07-04 | 山东大学 | 3-甲氧基苯甲酰胺衍生物及其制备方法与应用 |
BR112014021935A2 (pt) | 2012-03-05 | 2019-09-24 | Gilead Calistoga Llc | formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona |
JP2015532650A (ja) | 2012-09-05 | 2015-11-12 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 非生物的植物ストレスに対する活性物質としての置換された2−アミドベンズイミダゾール類、2−アミドベンゾオキサゾール類および2−アミドベンゾチアゾール類またはそれらの塩の使用 |
MX362855B (es) * | 2012-09-26 | 2019-02-20 | Merck Patent Gmbh | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). |
NZ720867A (en) | 2013-12-20 | 2018-01-26 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
JP2017503833A (ja) * | 2014-01-23 | 2017-02-02 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | イカリイン誘導体 |
BR112016028642A2 (pt) | 2014-06-13 | 2017-08-22 | Gilead Sciences Inc | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. |
WO2016138574A1 (en) | 2015-03-02 | 2016-09-09 | Sinai Health System | Homologous recombination factors |
KR101896567B1 (ko) | 2015-07-23 | 2018-09-07 | 인스티튜트 큐리 | 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도 |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
KR20190107656A (ko) | 2016-11-02 | 2019-09-20 | 이뮤노젠 아이엔씨 | 항체-약물 콘주게이트 및 parp 억제제로 병용 치료 |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018197461A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
CA3092779A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US26565A (en) * | 1859-12-27 | Improved register for railroad-cars | ||
US3169129A (en) * | 1963-05-10 | 1965-02-09 | American Cyanamid Co | 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones |
USRE26565E (en) | 1966-03-02 | 1969-04-29 | Table iii | |
GB1338235A (en) * | 1970-12-15 | 1973-11-21 | May & Baker Ltd | Azapurinones |
US4323503A (en) * | 1976-08-04 | 1982-04-06 | Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France | Substituted 2,3-alkylene di (oxy) benzamides and derivatives |
US4281127A (en) * | 1979-07-09 | 1981-07-28 | Hoffmann-La Roche Inc. | Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives |
EP0054132B1 (de) * | 1980-12-12 | 1984-10-10 | Dr. Karl Thomae GmbH | Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen |
DE3202898A1 (de) | 1982-01-29 | 1983-08-11 | Geze Gmbh, 7250 Leonberg | Antriebseinheit fuer fluegel, insbesondere schiebefluegel von tueren o.dgl. |
DE3220898A1 (de) * | 1982-06-03 | 1983-12-08 | Dr. Karl Thomae Gmbh, 7950 Biberach | Verfahren zur herstellung von pyrimidinonen und ihren saeureadditionssalzen |
US4499303A (en) * | 1983-09-27 | 1985-02-12 | Research Corporation | Antihyperlipidemic N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides |
US5032617A (en) * | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
DE3690206T1 (de) * | 1985-05-03 | 1987-09-17 | ||
JPS62258368A (ja) * | 1986-03-10 | 1987-11-10 | Agency Of Ind Science & Technol | キナゾリン−4−オンの製造方法 |
EG18188A (en) * | 1986-05-01 | 1992-09-30 | Pfizer Ltd | Process for preparation anti-arhythmia agents |
ZA885929B (en) * | 1987-08-25 | 1989-04-26 | Oxi Gene Inc | Agents for use in tumor or cancer cell killing therapy |
CA2020073A1 (en) * | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
US5254692A (en) * | 1990-04-06 | 1993-10-19 | Bayer Aktiengesellschaft | 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines |
GB9011833D0 (en) * | 1990-05-25 | 1990-07-18 | Collins Mary K L | Inhibition of viral infection |
US5238942A (en) * | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
DE4142366A1 (de) * | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US5464871A (en) * | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
WO1993007868A1 (en) * | 1991-10-22 | 1993-04-29 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as anti-tumor and anti-retroviral agents |
US5223539A (en) * | 1991-11-22 | 1993-06-29 | G. D. Searle & Co. | N,n-di-alkyl(phenoxy)benzamide derivatives |
GB9126260D0 (en) * | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
-
1994
- 1994-03-09 GB GB9404485A patent/GB9404485D0/en active Pending
-
1995
- 1995-03-09 JP JP7523316A patent/JPH09510704A/ja active Pending
- 1995-03-09 EP EP98202103A patent/EP0897915B1/de not_active Expired - Lifetime
- 1995-03-09 DE DE69524641T patent/DE69524641T2/de not_active Expired - Fee Related
- 1995-03-09 WO PCT/GB1995/000513 patent/WO1995024379A1/en active IP Right Grant
- 1995-03-09 AT AT98202103T patent/ATE231494T1/de not_active IP Right Cessation
- 1995-03-09 CN CN95192011A patent/CN1081624C/zh not_active Expired - Fee Related
- 1995-03-09 AT AT98202102T patent/ATE210651T1/de not_active IP Right Cessation
- 1995-03-09 DE DE69529482T patent/DE69529482T2/de not_active Expired - Fee Related
- 1995-03-09 DE DE69512036T patent/DE69512036T2/de not_active Expired - Fee Related
- 1995-03-09 EP EP98202102A patent/EP0879820B1/de not_active Expired - Lifetime
- 1995-03-09 ES ES98202102T patent/ES2169472T3/es not_active Expired - Lifetime
- 1995-03-09 DK DK95910653T patent/DK0749415T3/da active
- 1995-03-09 DK DK98202102T patent/DK0879820T3/da active
- 1995-03-09 PT PT98202102T patent/PT879820E/pt unknown
- 1995-03-09 EP EP95910653A patent/EP0749415B1/de not_active Expired - Lifetime
- 1995-03-09 AT AT95910653T patent/ATE184271T1/de not_active IP Right Cessation
- 1995-03-09 CA CA002184747A patent/CA2184747C/en not_active Expired - Fee Related
- 1995-03-09 ES ES95910653T patent/ES2135707T3/es not_active Expired - Lifetime
-
1996
- 1996-08-30 US US08/706,326 patent/US5756510A/en not_active Expired - Fee Related
-
1998
- 1998-04-08 US US09/056,928 patent/US6015827A/en not_active Expired - Fee Related
-
1999
- 1999-11-18 GR GR990402976T patent/GR3031886T3/el unknown
- 1999-11-24 US US09/448,485 patent/US6316455B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
GR3031886T3 (en) | 2000-02-29 |
GB9404485D0 (en) | 1994-04-20 |
DK0749415T3 (da) | 2000-03-20 |
EP0879820B1 (de) | 2001-12-12 |
ATE210651T1 (de) | 2001-12-15 |
CA2184747A1 (en) | 1995-09-14 |
CN1081624C (zh) | 2002-03-27 |
DE69512036D1 (de) | 1999-10-14 |
US6015827A (en) | 2000-01-18 |
CN1143358A (zh) | 1997-02-19 |
EP0897915A1 (de) | 1999-02-24 |
DE69529482D1 (de) | 2003-02-27 |
AU1856595A (en) | 1995-09-25 |
AU693167B2 (en) | 1998-06-25 |
EP0897915B1 (de) | 2003-01-22 |
US5756510A (en) | 1998-05-26 |
DE69529482T2 (de) | 2003-06-12 |
DE69524641T2 (de) | 2002-08-14 |
DE69524641D1 (de) | 2002-01-24 |
EP0749415A1 (de) | 1996-12-27 |
PT879820E (pt) | 2002-06-28 |
US6316455B1 (en) | 2001-11-13 |
JPH09510704A (ja) | 1997-10-28 |
DK0879820T3 (da) | 2002-04-02 |
CA2184747C (en) | 2003-10-14 |
EP0749415B1 (de) | 1999-09-08 |
ES2169472T3 (es) | 2002-07-01 |
ATE184271T1 (de) | 1999-09-15 |
EP0879820A1 (de) | 1998-11-25 |
WO1995024379A1 (en) | 1995-09-14 |
ATE231494T1 (de) | 2003-02-15 |
ES2135707T3 (es) | 1999-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69512036D1 (de) | Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns-reparaturenzyminhibitoren | |
EA199800184A1 (ru) | Соединение бензимидазола | |
AU2003301020A1 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
NO2013002I1 (no) | Aklidinium haogenid (Aklidinium bromid) | |
BR9911182A (pt) | Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto. | |
BG106586A (en) | Pyrazolopyramidines as therapeutic agents | |
NZ324887A (en) | Piperazine and piperidine compounds with analgesic effect | |
MY119623A (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
DK1107973T3 (da) | Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi | |
ES8802153A1 (es) | Procedimiento para preparar derivados de isoxazol y furano. | |
UA35557C2 (uk) | Похідні 1,2,4-оксадіазолілфеноксіалкілізоксазолу, що мають противірусну активність та фармацевтична композиція на їх основі | |
WO1999024022A3 (en) | Isoquinoline derivatives for treating disorders associated with 5ht7 receptors | |
DK0960111T3 (da) | Morphinderivat med analgesisk aktivitet | |
MY129935A (en) | Dihydropyridine derivatives useful in antitumor therapy | |
DK144685A (da) | Substituerede benzopyraner, fremgangsmaader til fremstilling deraf samt deres anvendelse i laegemidler | |
NO982863L (no) | Nye forbindelser med analgetisk effekt | |
PT861250E (pt) | Derivados de amidina e de isotioureia como inibidores de oxido nitrico sintase | |
PT1245564E (pt) | Derivados de benzamidina. | |
CA2352592A1 (en) | Quinazolinone compounds | |
CY2582B2 (en) | New imidazopyridines and oxazolopyridines | |
ZA9810361B (en) | Heterocyclic compounds having MMP and TNF inhibitory activity. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: ZEITLER, VOLPERT, KANDLBINDER, 80539 MUENCHEN |
|
8339 | Ceased/non-payment of the annual fee |